CTRI/2019/12/022361已完成2 期
An open label, parallel study to evaluate the steady state pharmacokinetics of Vitamin K2-7 capsules 350 mcg of Synergia Life Sciences Pvt. Ltd after multiple dose administered in normal, healthy, adult, human male subjects under fed condition
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Non-smokers, normal, healthy, adult, human male volunteers between 18 to 45 years of age (both inclusive).
- •2. Having a Body Mass Index (BMI) between 18.5 to 30.0 (both inclusive), calculated as weight in kg / height in sq.m.
- •3. Not having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG and X-ray chest (P/A view) recordings.
- •4. Able to understand and comply with the study procedures, in the opinion of the investigator.
- •5. Able to give voluntary written informed consent for participation in the study.
排除标准
- •1. Known hypersensitivity to Vitamin K2-7 or any excipients or any related drug or any substance.
- •2.History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •3. Ingestion of a medication (prescribed & over the counter (OTC) medication including herbal remedies) at any time within 14 days prior to first dosing. In any such case subject selection will be at the discretion of the Principal Investigator / designee.
- •4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •5. A recent history of harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc), or consumption of alcohol or alcoholic product within 48 hours prior to check-in.
- •6. Smokers or who have smoked within last 06 months prior to start of the study.
- •7. Consumption of natto or any fermented food products such as Dosa, Ideli, Curd, Yogurt and other vitamin K containing products within 72 hours prior to check in.
- •8. The presence of clinically significant abnormal laboratory values during screening.
研究者
相似试验
进行中(未招募)
不适用
Pharmacokinetics and Safety of Doripenem in hospitalized Pediatric Patients from 3 Months to 17 Years of AgeBacterial infectionsEUCTR2011-005159-15-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development, L.L.C.50
进行中(未招募)
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple Sclerosis (RRMS)MedDRA version: 20.1Level: LLTClassification code: 10039720Term: Sclerosis multiple Class: 10029205MedDRA version: 21.1Level: PTClassification code: 10063399Term: Relapsing-remitting multiple sclerosis Class: 100000004852CTIS2023-507313-94-00F. Hoffmann-La Roche AG24
进行中(未招募)
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple SclerosisRelapsing-remitting multiple sclerosis (MS)MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002667-34-PLF. Hoffmann-La Roche Ltd36
进行中(未招募)
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple SclerosisMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersRelapsing-remitting multiple sclerosis (MS)MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002667-34-ITF. HOFFMANN - LA ROCHE LTD.36
进行中(未招募)
1 期
Safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted of host alloreactive T-cells, in patients with beta-thalassemia major who received a hematopoietic stem cell transplantation from a haploidentical donorPatients with beta-thalassemia major who are eligible for a haploidentical HSCTMedDRA version: 19.0 Level: LLT Classification code 10054661 Term: Thalassemia major System Organ Class: 100000004850EUCTR2016-002959-17-GBKiadis Pharma Netherlands B.V.10
